BioCentury
ARTICLE | Company News

CVTX receives milestone

April 10, 2000 7:00 AM UTC

CV Therapeutics received a $6.5 million milestone from Biogen (BGEN) triggered by the completion in February of a Phase II trial of CVTX's CVT-124 adenosine A1 receptor antagonist to treat congestive ...